Alpha-emitting radiopharmaceuticals gain attention in metastatic castration-resistant prostate cancer

Dr. Johann De Bono and Dr. Pedro Barata reviewed the current landscape of alpha-emitting radiopharmaceuticals for patients with metastatic castration-resistant prostate cancer (mCRPC).

They highlighted radium-223 dichloride as the most established agent and discussed how recent data from the PEACE III trial may expand its use.

The conversation placed the therapy within a broader series on radiopharmaceutical strategies, including combination approaches and patient selection.

While the PEACE III results were not detailed, the experts suggested that the findings could influence treatment sequencing and future research directions.